Independent briefing
A daily briefing of sourced, fact-only updates on molecular residual disease, ctDNA, and MRD-relevant biomarkers across cancer types. Edited by Alan Tan, a genitourinary hematologist-oncologist. MRD and biomarker items are listed ahead of other news from the same stretch of days.
A free weekly MRD Watch email. No send date is set. Subscribe
Edited by Alan Tan, MDLatest Gynecologic items. Open the Gynecologic page.
How it works
“No evidence of disease” means the scan did not show a tumor. Alan Tan, MD, puts the gap this way, as an illustration rather than a cutoff: “To the human eye, a clear scan can still hide around 200 million cancer cells.” MRD testing, especially ultrasensitive MRD, looks for that leftover signal in blood.
How testing worksNov 15, 2026 ET
No update is dated today. The latest verified items are below, with MRD and biomarker reports ranked first.
Pinned items, then MRD and biomarker reports, then newer dates.
An ASCO 2026 retrospective cohort of 72 patients with high-grade epithelial ovarian cancer, 69 of whom were in clinical remission, found ctDNA positivity in 30 and second-look laparoscopy positivity in 33; on multivariable analysis ctDNA positivity predicted shorter progression-free survival (HR 4.35; 95% CI 2.17 to 8.72).
Journal of Clinical Oncology
The leading list already holds every item on file.